Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly will raise the UK list price of its weight-loss and type 2 diabetes treatment Mounjaro by up to 170% to be in line ...

Two leading cardiology groups have joined forces to position heart failure as a preventable condition, encouraging clinicians ...

Now, it’s worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 184% for ...

Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...

Novo Nordisk ( ($NVO) ) has shared an update. On August 8, 2025, Novo Nordisk disclosed transactions involving the sale of shares by board members ...

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...